Epivir

See also: Generic Epivir-HBV

Epivir is a brand name of lamivudine, approved by the FDA in the following formulation(s):

EPIVIR (lamivudine - solution; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: November 17, 1995
  
  Strength(s): 10MG/ML ^[RLD]

EPIVIR (lamivudine - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: November 17, 1995
  
  Strength(s): 150MG ^[AB]


• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: June 24, 2002
  
  Strength(s): 300MG ^[RLD][AB]

Has a generic version of Epivir been approved?

A generic version of Epivir has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Epivir and have been approved by the FDA:

lamivudine tablet; oral

• 
  Manufacturer: APOTEX
  
  Approval date: December 2, 2011
  
  Strength(s): 150MG ^[AB], 300MG ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA LTD
  
  Approval date: November 17, 2011
  
  Strength(s): 150MG ^[AB], 300MG ^[AB]

Note: No generic formulation of the following product is available.

• lamivudine - solution; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Epivir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Crystalline oxathiolane derivatives
  Patent 5,905,082
  Issued: May 18, 1999
  Inventor(s): Roberts; Tony Gordon & Evans; Paul
  Assignee(s): Glaxo Group Limited
  (-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
  
  Patent expiration dates:
  
  
  • May 18, 2016
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • May 18, 2016
    
  
  
  
  • November 18, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing lamivudine
  Patent 6,004,968
  Issued: December 21, 1999
  Inventor(s): Casey; Warren Michael & Nguyen; Ngoc-Anh Thi
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.
  
  Patent expiration dates:
  
  
  • March 20, 2018
    
  
  
  
  • September 20, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Epivir Consumer Information (Drugs.com)
• Epivir Consumer Information (Wolters Kluwer)
• Epivir Solution Consumer Information (Wolters Kluwer)
• Epivir Consumer Information (Cerner Multum)
• Epivir Advanced Consumer Information (Micromedex)
• Lamivudine Consumer Information (Wolters Kluwer)
• Lamivudine Solution Consumer Information (Wolters Kluwer)
• Lamivudine Consumer Information (Cerner Multum)
• 3tc Advanced Consumer Information (Micromedex)
• Epivir A/F Advanced Consumer Information (Micromedex)
• Heptovir Advanced Consumer Information (Micromedex)
• Lamivudine Advanced Consumer Information (Micromedex)
• Lamivudine AHFS DI Monographs (ASHP)